BioComp Pharmaceuticals specializes in developing, sourcing, and bringing generic drugs to market. As a company positioned in the highly competitive and fast-growing US generic drug market, BioComp is well-placed to benefit from the market's projected continued growth. The generic drug market has experienced significant expansion over the past 30 years, with generics now comprising the majority of prescriptions in the US, driven by their lower prices compared to brand drugs.

1. BioComp
Pharmaceuticals -
Positioned In A
Growth Market
TERRELL HERRING

2. Introduction
Residing in Doylestown, Pennsylvania, Terrell “Terry” Herring serves as
president of commercial operations for Mission Pharmacal. Terrell
Herring plays a leading role in all of the company’s subsidiaries including
BioComp Pharmaceuticals.
Founded in 2008, BioComp specializes in the development, sourcing,
and bringing to market of prescription generic drugs, offering its sizable
capabilities to strategic partners that are in need of commercial
solutions. BioComp is positioned in the highly competitive US generic
market which, according ResearchAndMarket.com, has experienced a
significant change over the past 30 years. Generics used to account for
only 20 percent of total prescriptions. Today they comprise the majority
of all drug prescriptions dispensed in the country.

3. BioComp Pharmaceuticals
The generic drug market CAGR from 2011 to 2107 was at 13 percent.
Factors that have contributed to the market’s multibillion dollars’
growth include the lower prices of generic drugs, which has resulted in
massive savings in healthcare expenses for governments and third-party
payers, as well as lowered patient copayments. Other factors include
the aging population and patent expiration of top performing innovator
drugs.
The market is projected to continue its growth with huge investments
being poured into new product categories. The next few years will also
witness patent expiration of some major drugs and more US
government approval of generic drugs.